, ,
Integral service around a transaction
BY : Diego GutiérrezNovember Thu, 2019

Bigfinity is an American Start Up, of Spanish origin and specialist in SaaS platforms for pharmaceutical and biotechnology industries, which has just sold part of its shares in a 15M$ round.

New investors include, among others, Atlantic Bridge or the investment vehicle of the multinational Honey Well.

For many years, the pharmaceutical industry has been very used to working on high margins, but, being regulated, it has never had much incentive to optimise.

However, the situation is changing, and this is reflected in the movements in the sector's corporate finances.


Bigfinity is an American Start Up based in San Francisco, but founded by Catalan entrepreneurs in 2014.

A cloud-based SaaS platform development company for the pharmaceutical and biotech industries that transforms manufacturing operations through the use of artificial intelligence and IoT technologies..


It has a system that captures all the data generated in the production of medicines through sensors and uploads it to the cloud.

Once there, its algorithms recommend the best ways to increase productivity.

The company is currently split into two companies:

  • San FranciscoThe company has ten employees, divided between the business development and marketing departments.
  • BarcelonaThe company has a staff of fifty between the technology development and quality analysis departments.


Just this November, Bigfinity sold part of its shares in a financing round valued at 15M$.

At the forefront of the operation was the private equity fund Atlantic Bridge and the multinational's investment vehicle Honey Well.

Also present was the Institut Catalá de Finances (ICF) through its latest investment vehicle ICF enture Tech II.

In doing so, it will strengthen its sales team in the US and Europe, as well as its user experience through the creation of departments.

Above all, however, it will boost the commercialisation of its product and strengthen its position in the market.

In addition, the system will also be refined to meet the needs of each customer.

But this is not the first time that the firm has made the sale part of their shares.

Already in 2007, it received €7.6M in a round led by the fund Crosslink Capital.


Bigfinity is also the second operation of the ICF enture Tech II fund.

It made its debut in September with the acquisition of a stake in the Catalan biotech firm Vytrus Biotech for €500,000.

With a volume of €20m, its participation is a sign of Bigfinity's commitment to the Catalan economy.



Born in 2009, Som Biotech uses artificial intelligence to offer therapeutic solutions to patients.

It wants to act as a catalyst in rare disease research and in the development of new, effective and safe medicines for rare diseases.

Recently, it has managed to capture 7M€ for growth in its second round of Series A funding.


Founded in 2017, this is a company Spin Off of the Catalan Institute of Cardiovascular Sciences (ICCC) and the Spanish National Research Council (CSIC).

Focused on the development of a new in vitro diagnostic device for myocardial ischaemia, Glycardial diagnostics has been able to lift 1.9M€ in its third financing round.

The M&A Professionals

Meet our services



Do you want to be up to date?


Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?